Ya está disponible para su consulta el artículo Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. The GOLD Randomized Clinical Trial Descárgalo aquí 

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2017 EXECUTIVE SUMMARY   Autores: Alan J. Garber, MD, PhD, FACE1; Martin J. Abrahamson, MD2; Joshua I. Barzilay, MD, FACE3; Lawrence Blonde, MD, FACP, FACE4; Zachary T. Bloomgarden, MD, MACE5; Michael A. Bush, MD6; Samuel…

Consulta aquí el artículo Standards or Medical Care in Diabetes 2017, publicado por la American Diabetes Association

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor  evolocumab: a prespecified secondary analysis of the FOURIER trial LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between progressively lower…

Está disponible para descarga el artículo Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Insulin Injections.   Autores: RoyW. Beck, MD, PhD; Tonya Riddlesworth, PhD; Katrina Ruedy, MSPH; Andrew Ahmann, MD; Richard Bergenstal, MD; Stacie Haller, RD, LD, CDE; Craig Kollman, PhD; Davida Kruger, MSN, APN-BC; Janet B….